Population pharmacokinetics of terfenadine

Pharmaceutical Research

Volumn 13, Issue 6, 1996, Pages 832-838

  Lalonde, Richard L ^a   Lessard, Denis ^a   Gaudreault, Jacques ^a  

^a MDS Inc   (Canada)

Author keywords

Carboxylic acid terfenadine; Nonliner mixed effects modeling; NONMEM; Population pharmacokinetics; Terfenadine

Indexed keywords

TERFENADINE;

ARTICLE; ASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; VOLUNTEER;

ADULT; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MASS SPECTROMETRY; MODELS, STATISTICAL; POPULATION; SPECTROMETRY, FLUORESCENCE; TERFENADINE;

EID: 0029980099     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016036624935     Document Type: Article

References (24)

1. D. R. Mathews, B. McNutt, R. A. Okerholm, M. Flicker, and G. McBride. Torsades de pointes occurring in association with terfenadine use. JAMA 266:2375-2376 (1991).
2. D. McTavish, K. L. Goa, and M. Ferrill. Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs 39:552-574 (1990).
3. K. J. Simmons, T. J. Martin, W. T. A. Watson, and F. E. R. Simons. Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. J Allergy. Clin. Immunol. 85:540-547 (1990).
4. M. G. Eller, B. J. Walker, L. Yuh, K. K. Antony, B. E. McNutt, and R. A. Okerholm. Absence of food effects on the pharmacokinetics of terfenadine. Biopharm. Drug. Dis. 13:171-177 (1992).
5. M. G. Eller, B. J Walker, P. A. Westmark, S. I. Ruherg, K. K. Antony, B. E. McNutt, and R. A. Okerholm. Pharmacokinetics of terfenadine in healthy elderly subjects. J. Clin. Pharmacol. 32:267-271 (1992).
6. P. K. Honig, D. C. Wortham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53:630-636 (1993).
7. P. K. Honig, D. C. Wortham, R. Hull, K. Zamani, J. E. Smith, and L. R. Cantilena. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33:1201-1206 (1993).
8. P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:231-238 (1992).
9. P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur. J. Clin. Pharmacol 45:41-46 (1993).
10. C. E. Cook, D. L. Williams, M. Myers, C. R. Tallent, G. A. Leeson, R. A. Okerholm, and G. J. Wright. Radioimmunoassay for terfenadine in human plasma. J. Pharm. Sci. 69:1419-1423 (1980).
11. R. A. Okerholm, D. L. Weiner, R. H. Hook, B. J. Walker, G. A. Leeson, S. A. Biedenbach, M. J. Cawein, T. D. Dusebout, G. J. Wright, M. Myers, V. Schindler, and C. E. Cook. Bioavailability of terfenadine in man. Biopharm. Drug. Dis. 2:185-190 (1981).
12. C. H. Yun, R. A. Okerholm, and F. P. Guengerich. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of Cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug. Melab. Dispos. 21:403-409 (1993).
13. + channel cloned from the human heart. Mol. Pharmacol. 44:1240-1245 (1993).
14. P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518 (1993).
15. B. P. Monahan, C. L. Ferguson, E. S. Killeavy, B. K. Lloyd, J. Troy, and L. R. Cantilena. Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790 (1990).
16. D. Lessard, W. Menabo, J. Desrochers, and C. Menard. A high sensitivity HPLC/MS method for the determination of terfenadine in human plasma. Pharm. Res. 10:5394 (1993).
17. S. L. Beal, L. B. Sheiner, A. J. Boeckmann. NONMEM users guide. San Francisco: NONMEM Project Group, University of California, 1993.
18. A. J. Boeckmann, L. B. Sheiner, S. L. Beal. NONMEM users guide Part V. Chapter 5. San Francisco: NONMEM Project Group, University of California, 1992.
19. M. Gibaldi and D. Perner. Noncompartmental analysis based on statistical moment. In Pharmacokinetics, Marcel Dekker, New York, 1982, pp.409-417.
20. G. V. Belle, D. C. Martin. Sample size as a function of coefficient of variation and ratio of means. Am. Statistician. 47:165-167 (1993).
21. S. Surapaneni and S. K. W. Khalil. A preliminary pharmacokinetic study of the enantiomers of the terfenadine acid metabolite in humans. Chirality 6:479-483 (1994).
22. N. Rao, D. R. Weilert, M. G. A. Grace, M. G. Eller, and S. J. Weir. Pharmacokinetics of terfenadine-acid-metabolite, MDL 16.445, in healthy geriatric subjects. Pharm. Res. 12:S-386 (1995).
23. J. B. Houston and G. Taylor. Drug metabolite concentration-time profiles: influence of route of drug administration. Br. J. Clin. Pharmacol. 17:385-394 (1984).
24. L. B. Sheiner and T. M. Ludden. Population pharmacokinetics/ pharmacodynamics. Annual Review of Pharmacoloogy and Toxicology 32:185-209 (1992).